SureNano Science Ltd. News Releases

SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development

Mon, 23 Feb 2026 09:00:00 -0500

GlucaPharm is developing GEP44, a novel, patented peptide (similar in function to Ozempic®, Wegovy®, Mounjaro®, but with reduced risk of adverse events) discovered by researchers at Syracuse University.Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) ("SureNano" or the "Company") is pleased to announce that it has completed the acquisition of GlucaPharm Inc. ("GlucaPharm"), a next-generation glucagon-like peptide ("GLP")...

SureNano Announces Stock Option Grant

Fri, 12 Dec 2025 09:18:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces that it has granted 1,500,000 stock options to various directors, officers, and Consultants of the Company. The options will vest immediately and may be exercised at an exercise price of CAD $0.18 per common share, for a period of 5 years from the date of issuance or earlier in accordance with the Company's incentive stock option...

SureNano Announces Closing of $1,250,000 Private Placement

Wed, 10 Dec 2025 09:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce, as a follow-up to its news release dated November 5, 2025, that it has closed its non-brokered private placement to raise $1,250,000 through the issuance of 10,000,000 units (each a "Unit") at a price of $0.125 per Unit. Each Unit is comprised of one common share (a "Common Share") and one Common Share purchase warrant (each a...

SureNano Announces Non-Binding Letter of Intent to Negotiate Proposed Transaction of GlucaPharm Inc. for GLP-1 Drug Development

Wed, 19 Nov 2025 16:30:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with GlucaPharm Inc. ("GlucaPharm"), to conduct legal, technical and financial due diligence on GlucaPharm and its license to the intellectual property as described below (the "Proposed Transaction"). If the Company elects to proceed following the conclusion of its...

SureNano Announces Private Placement

Wed, 05 Nov 2025 18:36:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - November 5, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces its intention to complete a private placement for proceeds of up to $1,250,000 (the "Private Placement"). The Private Placement will consist of the sale of up to 10,000,000 units (each a "Unit") at a price of $0.125 per Unit. Each Unit will be comprised of one common share (a "Common Share") and one Common Share purchase warrant (each a...

SureNano Closes Financing

Fri, 19 Sep 2025 16:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces that it has closed a private placement financing of 2,450,000 common shares at a price of $0.10 per share. Total proceeds of $245,000 were received by the Company, including $85,000 in debt conversion. The Company intends to use the cash proceeds for operating expenses, including legal and audit fees and general working capital. No part of...

SureNano Announces Funding, Debt Settlement and AGSM Results

Fri, 22 Aug 2025 09:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 22, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces its intention to complete a recapitalization consisting of a debt settlement with an insider for $85,000 ("Debt Settlement") and a private placement for proceeds of up to $215,000 (the "Private Placement"). Up to 3,000,000 Private Placement and Debt Settlement shares in total be issued at a price of $0.10 per share subject to CSE approval....